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and has poor transplant outcome with a high TRM, a lower EFS
and a lower OS.
3. Group 2 (0.30- 0.85  108/kg) had the best overall engraft-
ment (both ANC and PLT) of close to 80%. TRM was lowest in
this group at 13% but the rate of relapse was higher than the other
groups.
4. Group 3 (0.86- 2.83  108/kg) received higher than the
median MNC cell dose. Compared to Group 2 though this group
shows a lower engraftment it shows comparable EFS. This group
shows that a higher cell dose results in higher TRM (8 of 9
patients) and fewer relapse (4%).
Transplant Outcome
MNC dose group
(x108/kg
Overall
(0.08- 2.83)
(1)
<0.29
(2)
0.30- 0.85
(3)
> 0.86
n 92 19 46 27
ANC engraftment 63; 68.5% 10; 52.6% 38; 79.2% 15; 55.6%
PLT engraftment 58; 63% 10; 52.6% 36; 78.3% 12; 44.4%
Days to ANC 24 36 26 18
Days to PLT 44 56 46 34
TRM 22; 23.9% 8; 42% 6; 13% 8; 29.6%
Relapse 13; 14.1% 3; 15.8% 9; 19.6% 1; 3.7%
EFS 57; 62% 8; 34.8% 31; 67.4% 18; 66.7%
OS (days) 706 326 1396 603
256
HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGI-
CAL DISEASES AT YEDITEPE UNIVERSITY HOSPITAL
Yirmibescik, S.1, Senkal, V.1, Kalayci, G.1, Aktas, S.1, Aydin, D.1,
Sonmezoglu, M.1, Kocagoz, S.1, Oyan, B.1, Koc, Y.1 1Stem Cell Trans-
plant Unit, Yeditepe University Hospital, Istanbul, Turkey.
Stem cell transplantation(SCT) is an effective treatment modality
in hematological malignancies. SCT Unit at Yeditepe University
Hospital(CIC-919) was activated in October 2005 and accredited
for unrelated SCT by EBMT in April 2006. Until September 2006,
13 autologous and 17 allogeneic (4 unrelated) SCT have been
performed. Diagnosis of patients who underwent auto-SCT con-
sisted of HL(n6), NHL(n4) and myeloma (MM, n3). Patients
undergoing allo-SCT had HL(n2), NHL(n2), MM(n3),
CML(n3), CML-BT(n3), AML(n2), ALL(n1), and Thalas-
semia(n1). Median age was 38,5 (20-65) years and mean time
from diagnosis to transplant was 2,3 years. Patients received a
mean number of 8 (2-18) salvage regimens prior to transplantation.
All patients engrafted and median engraftment period was 11
(8-14) days. Transplantation related mortality(TRM) was not ob-
served during the ﬁrst 100 days and follow-up. Median follow-up
period was 5,4 (1-10,5) months. During follow-up, 5 patients
(16%) relapsed and 2 patients died (6%). Of 28 (94%) surviving
patients, 24 (80%) are in CR. All patients (100%) were alive
following auto-SCT at day 100, only one patient with myeloma
died due to relapse at 9 months. In the allo-SCT group, 16 (94%)
of patients were alive at day 100, only one patient died due to
relapse of CML-BT. Post-transplant complications were CMV
viremia(n9), CMV colitis(n3), sinusoidal occlusion syn-
drome(n1), BK viremia and hemorrhagic cystitis(n2), renal
failure(n1). Reversible blindness due to hypophyseal tumor apo-
plexy in a patient at day 11 was successfully corrected by neuro-
surgery. Grade II- III acute GVHD was observed in 8 pa-
tients(47%). All patients with acute GVHD were successfully
treated without mortality. A patient with refractory ALL associated
with CNS and eye involvement achieved complete remission fol-
lowing allo-SCT combined with modulated radiotherapy (IMRT).
All 4 patients (100%) who underwent unrelated-SCT following
autologous transplantation complicated with relapsed-refractory
disease are alive and 3 were in CR at day 100 (2 HL,1 NHL). Of
7 patients undergoing allo-SCT as a second transplant, 6 (85%) are
alive; in this group, only one patient with MM (15%) died due to
relapse. The high survival rate (94%) achieved following autolo-
gous and/or allogeneic SCT including unrelated transplants, low
TRM (0%) and the high remission rate (80%) may be related to
team approach, 24-hour patient follow-up, and effective manage-
ment of acute GVHD.
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VALIDATION OF THE HEMATOPOIETIC CELL TRANSPLANTATION-CO-
MORBIDITY INDEX (HCT-CI) FOR NON-RELAPSE MORTALITY (NRM)
AND SURVIVAL AFTER MATCHED UNRELATED DONOR SCT
Kovacsovics, T.1,2, Hayes-Lattin, B.1,2, Riegert, K.1, Subbiah, N.1,
Curtin, P.T.1,2, Leis, J.F.1,2, Mauro, M.M.1,2, Epner, E.E.1,2,
Fleming, W.H.1,2, Meyers, G.M.1,2, Deininger, M.W.1,2, Dunn, A.1,
Maziarz, R.T.1,2 1Center for Hematological Malignancies, OHSU,
Portland, OR; 2Oregon Cancer Institute, Portland, OR.
Background: The HCT-CI is a recently developed comorbidity
score which has been adapted to hematopoietic stem cell trans-
plantation, with higher scores associated to worse outcomes (Blood
2005;106:2912) . We determined the HCT-CI score in a cohort of
patients who underwent conventional MUD transplantation in a
single arm, single institution trial assessing efﬁcacy of a 3-drug
combination of cyclosporine, methotrexate and prednisone for
GVHD prophylaxis from 1996-2005.
Methods: The analysis included all patients undergoing MUD
transplant who received GVHD prophylaxis with cyclosporine 2
mg/kg iv BID from day -2, methotrexate 15 mg/m2 iv on day 1
and 10 mg/m2 iv on days3 and6, and methylprednisolone 0.25
mg/kg iv BID beginning on day 7 and tapering at day 28.
Patients were stratiﬁed by disease risk per CIBMTR classiﬁcation.
The comorbidities were obtained by retrospective chart review and
scored according to the HCT-CI score.
Results: 133 patients received the 3 drug-regimen, including 26
% with low-, 36 % with intermediate- and 38 % with high-risk
disease. Diagnoses included acute leukemia in 50%, MDS in 9.8%,
CML in 16.5%, lymphoma in 18.1%, multiple myeloma in 3.0%.
52 % were older than 40. Source of stem cells was PBSC in 47.4%,
marrow in 51.9%. and both in 0.8%. Among the 133 patients,
22%, 31% and 47% had HCT-CI scores of 0 vs 1-2 vs 3,
respectively. Overall NRM was 26.3% and 36.8%, at 3 months and
1 year, respectively. Three and 12 month NRM was 13.3%, 14.6
and 40.3% and 30%, 22% and 50% among patients with scores of
of 0 vs 1-2 vs 3, respectively. HR rates for 3 month NRM were
1.10 and 3.7 for HCT-CI scores 1-2 and 3. Kaplan-Meier as-
sessment showed 42.1% 5 year OS for the whole cohort. OS of
60%, 48.% and 28.1% were observed in patients with scores of of
0 vs 1-2 vs 3, respectively (p  0.05). No statistically signiﬁcant
differences in OS were observed between low-, intermediate- and
high-risk CIBMTR disease groups.
Conclusion: HCT-CI was a powerful predictor of 3 and 12
month NRM, as well as of 5 year OS in this cohort of MUD
patients. It will be useful for patient stratiﬁcation in clinical trials
and for treatment allocation.
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SYNGENEIC STEM CELL TRANSPLANTATION FOR APLASTIC ANEMIA IN
AN HIV PATIENT
Longoni, H.O.1, Binaghi, M.A.1, Kohan, A.I.1, Lasala, M.B.1,
Banchieri, A.V.1, Minissale, C.J.1, Plana, J.L.1, Velicche, A.F.1,
Christin, M.P.1, Corach, D.2, Maissonnave, V.1, Calahonra, R.1 1Hos-
pital de Clinicas Jose´ de San Martı´n; University of Buenos Aires, Buenos
Aires, Argentina; 2Facultad de Farmacia y Bioquı´mica; University of
Buenos Aires, Buenos Aires, Argentina.
Allogeneic hematopoietic stem cell transplantation from HLA
identical siblings is an effective treatment for aplastic anemia in
young patients. Heavily transfused patiens have shown an increased
risk of graft rejection requiring a more intensive immunosuppres-
sive conditioning. Usually a combination of cyclophosphamide
(Cy) with total body irradiation (TBI) or more recently with
antithimocyte globuline (ATG) is used.
We report a 32 year old patient with haemorragic manifestations,
haemodynamic instability and pancytopenia, admitted to the Hos-
pital in February 2005. Bone marrow biopsy performed, conﬁrmed
the diagnosis of aplastic anemia, Human Immunodeﬁciency Virus
(HIV) seropositivity was assessed by 2 different methods. No other
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